Clinical Trials Browser

Phase 1/2 × Interventional × disitamab vedotin × Clear all

NCT06966453 2026-03-04

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06957561 2025-05-04

DIVON

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT06378242 2024-07-11

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Phase 1/2 Recruiting

High-risk Non-muscle Invasive Bladder Cancer